CLINICAL TRIALS PROFILE FOR FARXIGA
✉ Email this page to a colleague
All Clinical Trials for farxiga
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02235298 ↗ | Dapagliflozin Effects on Epicardial Fat | Completed | AstraZeneca | Phase 4 | 2015-09-01 | The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart. |
| NCT02235298 ↗ | Dapagliflozin Effects on Epicardial Fat | Completed | University of Miami | Phase 4 | 2015-09-01 | The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart. |
| NCT02371187 ↗ | Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? | Completed | AstraZeneca | Phase 2 | 2015-06-01 | Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training. |
| NCT02371187 ↗ | Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? | Completed | Christopher Bell | Phase 2 | 2015-06-01 | Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training. |
| NCT02372955 ↗ | Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes | Unknown status | Gulf Regional Research & Educational Services, LLC | Phase 4 | 2015-02-01 | Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers clinic SBP is unknown. The primary objective of the study is to determine the effect of dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index (AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion, and Intravascular volume status will be recorded. The study will involve 21 subjects for a duration of 16 weeks. |
| NCT02429258 ↗ | Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin | Completed | AstraZeneca | Phase 4 | 2015-05-01 | Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for farxiga
Condition Name
Clinical Trial Locations for farxiga
Trials by Country
Clinical Trial Progress for farxiga
Clinical Trial Phase
Clinical Trial Sponsors for farxiga
Sponsor Name
